medigraphic.com
ISSN 2448-5640 (Impreso)
Diario Oficial de la Sociedad Mexicana de Cirugía Cardiaca, A.C., y del Colegio Mexicano de Cirugía Cardiovascular y Torácica, A.C.

2020, Número 3

Siguiente >>

Cir Card Mex 2020; 5 (3)


Surgical management of the tricuspid valve endocarditis

Rendón-Elías FG, de la Cerda-Belmont GA, Anaya-Medina G, Salas-Ríos CM, Hernández-Sánchez M, Fuentes-Puga V, Albores-Figueroa R, Goretti-Cépeda M, Gómez-Danés LH

Idioma: Ingles.
Referencias bibliográficas: 64
Paginas: 65-73
Archivo PDF: 360.03 Kb.


RESUMEN

Objetivo. Evaluar el manejo quirúrgico de la endocarditis infecciosa de la válvula tricúspide y sus complicaciones, de 2000 a 2019 en un centro terciario mexicano. Métodos. Se analizaron detalles de 22 pacientes consecutivos operados por endocarditis infecciosa de la válvula tricúspide desde septiembre de 2000 hasta diciembre de 2019. Resultados. Dos (9%) pacientes murieron en el hospital. El seguimiento fue completo en todos los pacientes. No hubo muertes tardías, 3 y 22 meses después del alta hospitalaria. El seguimiento se extendió de 2 a 72 meses y la supervivencia general fue del 95% y no hubo casos de endocarditis recurrente. Conclusión. Un diagnóstico temprano e indicación de tratamiento quirúrgico antes de la aparición de complicaciones y sepsis generalizada es la clave para mejorar el pronóstico.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the managementof infective endocarditis: The Task Force for the Management of InfectiveEndocarditis of the European Society of Cardiology (ESC). Endorsed by EuropeanAssociation for Cardio-Thoracic Surgery (EACTS), the European Associationof Nuclear 15. Medicine (EANM). Eur Heart J 2015; 36:3075-128.

  2. Murdoch DR, Corey GR, Hoen B, et al. Clinical presentation, etiology, and outcomeof infective endocarditis in the 21st century: The International Collaborationon Endocarditis -Prospective Cohort Study. Arch Intern Med 2009; 169:463-73.

  3. Gaca JG, Sheng S, Daneshmand M, et al. Current outcomes for tricuspid valveinfective endocarditis surgery 17. in North America. Ann Thorac Surg 2013;96:1374-81.

  4. Osler W. The Gulstonian lectures, on malignant endocarditis. BMJ 1885; 1:467-70.

  5. Hoen B, Alla F, Selton-Suty Ch, et al. Changing profile of infective endocarditis.JAMA 2002; 288:75-81.

  6. Fayad G, Leoy G, Devos P, et al. Characteristics and prognosis of patients requiringvalve surgery during active infective endocarditis. J Heart Valve Dis2011;20:223-8.

  7. Souto-Meriño CA, Cotter-Lemus LE, Assad-Gutierrez J, et al. Características dela endocarditis infecciosa en México. Arch Inst Cardiol Méx 1997; 67:46-50.

  8. Akinosoglou K, Apostolakis E, Marangos M, Pasvol G. Native valve right sideinfective endocarditis. Eur J Inter Med 2013; 24:510-9.

  9. Naidoo DP. Right-sided endocarditis in the non-drug addict. Postgrad Med J 1993;69:615-20.

  10. Chahoud J, Sharif Yakan A, Saad H, Kanj SS. Right-side infective endocarditisand pulmonary infiltrates: An Update. Cardiol Rev 2016; 24:230-7.

  11. Cabell CH, Jollis JG, Peterson GE, et al. Changing patient characteristics and theeffect on mortality in endocarditis. Arch Intern Med 2002; 162:90-4.

  12. Hussain ST, Witten J, Shrestha NK, Blackstone EH, Pettersson GB. Tricuspidvalve endocarditis. Ann Cardiothorac Surg 2017; 6:255-61.

  13. Seratnahaei A, Leung SW, Charnigo RJ, Cummings MS, Sorrell VL, Smith MD.The changing 'face' of endocarditis in Kentucky: An increase in tricuspid cases.Am J Med 2014;127, 04: 786.e1-6, doi: 10.1016/j.amjmed.2014.04.009.

  14. Moss R, Munt B. Injection drug use and right sided endocarditis. Heart2003;89:577-581.

  15. Athan E, Chu VH, Tattevin P, et al. ICE-PCS investigators. Clinical characteristicsand outcome of infective endocarditis involving implantable cardiac devices.JAMA 2012;307:1727-35.

  16. Millar BC, Moore JC. Emerging issues in infective endocarditis. Rev Biomed2004; 15:191-201.

  17. Netzer R, Zollinger E, Seiler C, Cerny A. Infective endocarditis: clinical spectrum,presentation and outcome. An analysis of 212 cases 1980-1995. Heart 2000;84:25-30.

  18. Baraki H, Saito S, Al Ahmad A, et al. Surgical treatment for isolated tricuspidvalve endocarditis long-term follow-up at a single institution. Circ J 2013;77:2032-7.

  19. Shrestha NK, Jue J, Hussain ST, et al. Injection drug use and outcomes after surgicalintervention for infective endocarditis. Ann Thorac Surg 2015;100:875-82.

  20. Miró JM, del Río A, Mestres CA. Infective endocarditis and cardiac surgery inintravenous drug abusers and HIV-1 infected patients. Cardiol Clin 2003; 21:167-84, v-vi.

  21. Frontera JA, Gradon JD. Right-side endocarditis in injection drug users: review ofproposed mechanisms of pathogenesis. Clin Infect Dis 2000;30:374-9.

  22. Musci M, Siniawski H, Pasic M, et al. Surgical treatment of right-sided activeinfective endocarditis with or without involvement of the left heart: 20-year singlecenter experience. Eur J Cardiothorac Surg 2007; 32:118-25.

  23. Carozza A, De Santo LS, Romano G, et al. Infective endocarditis in intravenousdrug abusers: patterns of presentation and long-term outcomes of surgical treatment.J Heart Valve Dis 2006; 15:125-31.

  24. Thalme A, Westling K, Julander I. In-hospital and long- term mortality in infectiveendocarditis in injecting drug users compared to non-drug users: a retrospectivestudy of 192 episodes. Scand J Infect Dis 2007; 39:197-204.

  25. Sohail MR, Uslan DZ, Khan AH, et al. Infective endocarditis complicating permanentpacemaker and implantable cardioverter-defibrillator infection. Mayo ClinProc 2008; 83:46-53.

  26. Tarakji KG, Wilkoff BL. Cardiac implantable electronic device infections: facts,current practice, and the unanswered questions. Curr Infect Dis Rep 2014;16:425.doi: 10.1007/s11908-014-0425-x.

  27. Yamane K, Hirose H, Bogar LJ, Cavarocchi NC, Diehl JT. Surgical treatment ofinfective endocarditis in patients undergoing chronic hemodialysis. J Heart ValveDis 2012;21:774-82.

  28. Gottardi R, Bialy J, Devyatko E, et al. Midterm follow-up of tricuspid valve reconstructiondue to active infective endocarditis. Ann Thorac Surg 2007; 84:1943-8.

  29. Pfannmueller B, Kahmann M, Davierwala P, et al. Tricuspid valve surgery in patientswith isolated tricuspid valve endocarditis: analysis of perioperative parametersand long-term outcomes. Thorac Cardiovasc Surg 2017;65:626-33.

  30. Bayer AS, Bolger AF, Taubert KA, et al. Diagnosis and management of infectiveendocarditis and its complications. Circulation 1998; 98: 2936-48.

  31. Ebtia M, Dewa D. Infective endocarditis revisted: Clinical manifestations andechocardiographic finding of patients with infective endocarditis. JACC 2012;59:135-40.

  32. Nihoyannopoulos P, Oakley CM, Exadactylos N, Ribeiro P, Westaby S, Foale RA.Duration of symptoms and the effects of a more aggressive surgical policy: twofactors affecting prognosis of infective endocarditis. Eur Heart J 1985; 6:380–90.

  33. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayedantibiotic treatment for hospital-acquired staphylococcus aureus bacteremia. ClinInfect Dis 2003; 36:1418–23.

  34. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for themanagement of patients with valvular heart disease: a report of the American Collegeof Cardiology/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol 2014;63:e57–185.

  35. Pérez-Vázquez A, Fariñas MC, García-Palomo JD, Bernal JM, Revuelta JM,González-Macías J. Evaluation of the Duke criteria in 93 episodes of prostheticvalve endocarditis: could sensitivity be improved? Arch Intern Med 2000;160:1185–91.

  36. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for thediagnosis of infective endocarditis. Clin Infect Dis 2000; 30:633-8.

  37. Habets J, Tanis W, Reitsma JB, et al. Are novel non-invasive imaging techniquesneeded in patients with suspected prosthetic heart valve endocarditis? A systematicreview and meta- analysis. Eur Radiol 2015;25:2125–33.

  38. Fagman E, Perrotta S, Bech-Hanssen O, et al. ECG-gated computed tomography:a new role for patients with suspected aortic prosthetic valve endocarditis. EurRadiol 2012;22:2407–14.

  39. Habets J, Tanis W, van Herwerden LA, et al. Cardiac computed tomography angiographyresults in diagnostic and therapeutic change in prosthetic heart valveendocarditis. Int J Cardiovasc Imaging 2014; 30:377–87.

  40. Feuchtner GM, Stolzmann P, Dichtl W, et al. Multislice computed tomographyin infective endocarditis: comparison with transesophageal echocardiography andintraoperative findings. J Am Coll Cardiol 2009; 53:436-44.

  41. Saby L, Laas O, Habib G, et al. Positron emission tomography/computed tomographyfor diagnosis of prosthetic valve endocarditis: increased valvular 18F-fluorodeoxyglucoseuptake as a novel major criterion. J Am Coll Cardiol 2013;61:2374-82.

  42. Pizzi MN, Roque A, Fernández-Hidalgo N, et al. Improving the diagnosis of infectiveendo- carditis in prosthetic valves and intracardiac devices with 18F-fluorodeoxyglucosepositron emission tomography/computed tomography: initial resultsat an infective endocarditis referral center. Circulation 2015; 132:1113–26.

  43. Erba PA, Conti U, Lazzeri E, et al. Added value of 99mTc-HMPAO-labeled leukocyteSPECT/CT in the characterization and management of patients with infectiousendocarditis. J Nucl Med 2012;53: 1235–43.

  44. Rouzet F, Chequer R, Benali K, et al. Respective performance of 18F-FDG PETand radio-labeled leukocyte scintigraphy for the diagnosis of prosthetic valve endocarditis.J Nucl Med 2014;55: 1980-5.

  45. Chambers J, Sandoe J, Ray S, et al. The infective endocarditis team: recommendationsfrom an international working group. Heart 2014; 100:524–7.

  46. Chirillo F, Scotton P, Rocco F, et al. Impact of a multidisciplinary managementstrategy on the outcome of patients with native valve infective endocarditis. Am JCardiol 2013; 112:1171-6.

  47. Baddour LM, Wilson WR, Bayer AS, et al., American Heart Association Committeeon Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council onCardiovascular Disease in the Young, Council on Clinical Cardiology, Council onCardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditisin adults: diagnosis, antimicrobial therapy, and management of complications.Circulation 2015; 132:1435–86.

  48. Ribera E, Gómez-Jimenez J, Cortes E, et al. Effectiveness of cloxacillin with andwithout gentamicin in short-term therapy for right-sided Staphylococcus aureusendocarditis. A randomized, controlled trial. Ann Intern Med 1996;125: 969–74.

  49. Fowler VG Jr., Boucher HW, Corey GR, et al. Daptomycin versus standard therapyfor bacteremia and endocarditis caused by Staphylococcus aureus. N Engl JMed 2006;355:653–65.

  50. Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin forStaphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis2009; 48:713-21.

  51. Morris AJ, Drinkovic D, Pottumarthy S, MacCulloch D, Kerr AR, West T. Bacteriologicaloutcome after valve surgery for active infective endocarditis: implicationsfor duration of treatment after surgery. Clin Infect Dis 2005; 41:187-94.

  52. 52.Muñoz P, Giannella M, Scoti F, et al., Group for the Management of InfectiveEndocarditis of the Gregorio Marañón Hospital (GAME). Two weeks of postsurgicaltherapy may be enough for high-risk cases of endocarditis caused by Streptococcusviridans or Streptococcus bovis. Clin Microbiol Infect 2012;18:293–9.

  53. Heldman AW, Hartert TV, Ray SC, et al. Oral antibiotic treatment of right-sidedstaphylococcal endocarditis in injection drug users: prospective randomized comparisonwith parenteral therapy. Am J Med 1996; 101:68–76.

  54. Iversen K, Høst N, Bruun NE, et al. Partial oral treatment of endocarditis. AmHeart J 2013;165: 116–22.

  55. Andrews MM, von Reyn CF. Patient selection criteria and management guidelinesfor outpatient parenteral antibiotic therapy for native valve infective endocarditis.Clin Infect Dis 2001;33: 203–9.

  56. Cervera C, del Río A, García L, et al., Hospital Clinic Endocarditis Study Group.Efficacy and safety of outpatient parenteral antibiotic therapy for infective endocarditis:a ten-year prospective study. Enfermedades Infecciosas y MicrobiologíaClínica 2011;29:587–92.

  57. Duncan CJ, Barr DA, Ho A, Sharp E, Semple L, Seaton RA. Risk factors for failureof outpatient parenteral antibiotic therapy (OPAT) in infective endocarditis. JAntimicrob Chemother 2013; 68:1650-4.

  58. Dawood MY, Cheema FH, Ghoreishi M, et al. Contemporary outcomes of operationsfor tricuspid valve infective endocarditis. Ann Thorac Surg 2015; 99:539-46.

  59. Gottardi R, Bialy J, Devyatko E, et al. Midterm follow-up of tricuspid valve reconstructiondue to active infective endocarditis. Ann Thorac Surg 2007; 84:1943-8.

  60. Tarola CL, Losenno KL, Chu MW. Complex tricuspid valve repair for infectiveendocarditis: leaflet augmentation,chordae and annular reconstruction. MultimedMan Cardiothorac Surg 2015. pii: mmv006. doi: 10.1093/mmcts/mmv006.

  61. Akinosoglou K, Apostolakis E, Koutsogiannis N, Leivaditis V, Gogos CA.Right-sided infective endocarditis: surgical management. Eur J Cardiothorac Surg2012; 42:470-9.

  62. Rabkin DG, Mokadam NA, Miller DW, Goetz RR, Verrier ED, Aldea GS. Longtermoutcome for the surgical treatment of infective endocarditis with a focus onintravenous drug users. Ann Thorac Surg 2012;93:51-7.

  63. Filsoufi F, Anyanwu AC, Salzberg SP, Frankel T, Cohn LH, Adams DH. Longtermoutcomes of tricuspid valve replacement in the current era. Ann Thorac Surg2005;80:845-50.

  64. Chang BC, Lim SH, Yi G, et al. Long-term clinical results of tricuspid valve replacement.Ann Thorac Surg 2006;81:1317-23.




2020     |     www.medigraphic.com